text
"[""\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 천원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\n셀트리온제약\n2000.11.17\n충청북도 청주시 청원군 오창읍 2산단로 82\n완제의약품 제조 및 판매\n637,884,365\n지분 50%초과보유\n해당(자산총액이 지배회사 자산총액의 10% 이상이상)\n셀트리온유럽\n2009.07.21\n4th Floor, 15 Basinghall Street, London,EC2V 5BR, UK\nEU 지역내 바이오시밀러 임상시험 수행\n2\n지분 50%초과보유\n해당없음\nCelltrion Global Safety Data Center\n2018.05.23\nUnit 2201, 22th floor, One Global Place, 5th Avenue Corner 25th Street,Bonifacio Global City, Taguig, 1634 Metro Manila, Philippines\n글로벌 의약품 안전성 데이터 관리\n2,123,610\n지분 50%초과보유\n해당없음\nCelltrion USA(*1)\n2018.07.24\n1209 Orange Street, City of Wilmington, County of New Castle, 19801\n케미컬의약품 판매유통망 구축\n92,120,901\n지분 50%초과보유\n해당(자산총액 750억원 이상)\nCelltrion Biopharma\n2019.02.13\n1st Floor, 6 Lapp's Quay, Cork, T12 VY7W, Ireland\n바이오시밀러 임상시험\n-\n지분 50%초과보유\n해당없음\nCelltrion Group Hongkong ltd\n2019.03.15\nUnit 1101, Enterprise Square, Tower 1,9 Sheung Yuet Road, Kowloon Bay, Kowloon, Hongkong\n바이오의약품 중국사업\n33,573,667\n지분 50%초과보유\n해당없음\nShanghai Vcell Biotech(*2)\n2019.04.09\n上海市浦東新區南彙新城鎭芦潮港路1969號219室\n바이오의약품 임상시험 등 연구개발\n1,417,712\n지분 50%초과보유\n해당없음\nCelltrion Asia Pacific PTE\n2020.08.12\n6 Eu Tong Sen Street #11-10C, The Central Singapore, 059817\n케미컬의약품 판매 및 연구개발\n371,554,346\n지분 50%초과보유\n해당(자산총액 750억원 이상)\n(*1) 공시서류 작성기준일 이후, 종속회사 Celltrion USA Inc.의 주식을 처분함에 따라 연결대상회사에서 제외되었습니다. 거래상대방은 특수관계인 (주)셀트리온헬스케어입니다.(*2) Celltrion Group Hongkong이 100%의 지분을 보유하고 있습니다.\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2022년 06월 30일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n3\n(주)셀트리온\n135011-0034038\n(주)셀트리온헬스케어\n134111-2007066\n(주)셀트리온제약\n110111-2112764\n비상장\n4\n(주)셀트리온홀딩스\n120111-0551178\n(주)셀트리온엔터테인먼트\n110111-4767757\n(주)셀트리온스킨큐어\n110111-1995723\n(주)티에스이엔씨\n120111-0379223\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2022년 06월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc\n비상장\n2006.07.14\n단순투자\n2,676,548\n987,889\n16.51\n116,349\n-\n-\n-\n987,889\n16.51\n116,349\n4,980,647\n766,345\n셀트리온 유럽\n비상장\n2009.07.21\n경영참여\n2\n1\n100.00\n2\n-\n-\n-\n1\n100.00\n2\n2\n-\n바이오톡스텍\n상장\n2009.07.28\n단순투자\n2,025,000\n1,631,134\n11.12\n13,081,695\n-\n-\n-831,879\n1,631,134\n11.12\n12,249,816\n88,252,746\n5,910,574\n제이티비씨\n비상장\n2017.09.20\n단순투자\n500,000\n100,000\n0.09\n67,986\n-\n-\n-24,261\n100,000\n0.09\n43,725\n368,300,727\n-23,591,277\n프리미어 글로벌 이노베이션 1호\n비상장\n2017.06.15\n단순투자\n250,000\n2,843\n6.67\n3,994,483\n112\n112,155\n-843,421\n2,955\n6.67\n3,263,217\n60,346,648\n12,429,027\n프리미어 글로벌 이노베이션 2호\n비상장\n2020.11.05\n단순투자\n250,000\n2,515\n5.56\n2,397,694\n885\n885,000\n-26,850\n3,400\n5.56\n3,255,844\n43,638,432\n-1,918,554\n매일방송\n비상장\n2011.03.17\n단순투자\n1,000,000\n250,981\n0.48\n1,475,167\n-\n-\n-\n250,981\n0.48\n1,475,167\n440,252,280\n23,013,981\n셀트리온제약\n상장\n2013.04.23\n경영참여\n50,057,259\n20,075,833\n54.93\n255,342,176\n602,274\n-\n-\n20,678,107\n54.93\n255,342,176\n637,884,365\n34,206,203\n2014 성장사다리-IMM 벤처펀드\n비상장\n2014.08.11\n일반투자\n2,000,000\n1,668\n20.00\n851,844\n-51\n-51,200\n-\n1,617\n20.00\n800,644\n4,006,064\n-90,127\n미래에셋 셀트리온신성장 투자조합 1호\n비상장\n2017.03.31\n일반투자\n6,250,000\n503\n50.00\n50,250,000\n-15\n-1,500,000\n-\n488\n50.00\n48,750,000\n106,972,220\n-979,570\n미래에셋 셀트리온바이오생태계육성펀드\n비상장\n2021.12.30\n일반투자\n5,000,000\n5,000\n38.46\n5,000,000\n-\n-\n-\n5,000\n38.46\n5,000,000\n12,991,440\n-8,560\nCelltrion Global Safety Data Center\n비상장\n2018.05.23\n경영참여\n1,106,930\n580,563\n99.99\n1,204,581\n-\n-\n-\n580,563\n99.99\n1,204,581\n2,123,610\n261,940\nCelltrion USA, Inc.\n비상장\n2018.07.24\n경영참여\n38,973\n3,050\n100.00\n6,951,601\n-\n-\n-\n3,050\n100\n6,951,601\n92,120,901\n9,180,721\nCelltrion Group Hongkong ltd\n비상장\n2019.04.01\n경영참여\n5,680,500\n7,023,270\n70.00\n8,086,365\n-\n-\n-\n7,023,270\n70.00\n8,086,365\n33,573,667\n-3,748,032\n셀트리온충북대 바이오메딕스\n비상장\n2018.07.18\n경영참여\n100,000\n20,000\n50.00\n100,000\n-\n-\n-\n20,000\n50.00\n100,000\n140,369\n-12,605\nIksuda Therapeutics Limited\n비상장\n2021.06.01\n경영참여\n9,031,863\n717,112\n17.79\n9,031,863\n-\n-\n-\n717,112\n17.79\n9,031,863\n20,470,018\n-16,351,756\nCelltrion Asia Pacific PTE\n비상장\n2020.11.23\n경영참여\n315,987,120\n283,600,000\n100.00\n315,987,120\n-\n-\n-\n283,600,000\n100.00\n315,987,120\n371,554,346\n-1,970,349\n아주-Solasta Life Science 4.0펀드\n비상장\n2022.05.16\n일반투자\n5,000,000\n-\n-\n-\n5,000,000,000\n5,000,000\n-\n5,000,000,000\n44.25\n5,000,000\n11,312,354\n-343,673\n합 계\n315,002,362\n-\n673,938,926\n5,000,603,205\n4,445,955\n-1,726,411\n5,315,605,567\n-\n676,658,470\n2,298,920,836\n36,754,288\n""]"
